Video
Author(s):
Elissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.
Elissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.
In a case study presented by Engel, a 13-year old patient with HIV and subsequent thrombocytopenia was treated with eltrombopag after showing poor response to first-line therapies including intravenous immunoglobulin (IVIg). The patient showed clinical response and has been asymptomatic since beginning the medication.
Engel says that she hopes this case brings light to the other potential uses of the medication. HIV thrombocytopenia is not a common disease, and the existing first-line therapies may not work for everybody, explains Engel. Further studies are needed to examine whether eltrombopag could receive an FDA indication for this patient population as well as other causes of thrombocytopenia.
Eltrombopag currently has FDA approval in other indications in adult patients, but is only approved for chronic immune thrombocytopenia in kids.
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
2 Commerce Drive
Cranbury, NJ 08512